R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.

Category Primary study
JournalAntimicrobial agents and chemotherapy
Year 2003
In 243 antiretroviral-naive human immunodeficiency-infected patients starting a first-line-protease inhibitor (mainly nelfinavir)-containing therapy, the presence of the polymorphism R57K in the protease at the inception of therapy was independently associated with a higher rate of virological failure.
Epistemonikos ID: 67965ab1fe584718e0db5a8bee13d54cf012f2f6
First added on: Dec 07, 2021